GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mega Lifesciences PCL (BKK:MEGA-R) » Definitions » Debt-to-Revenue

Mega Lifesciences PCL (BKK:MEGA-R) Debt-to-Revenue : 0.04 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Mega Lifesciences PCL Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Mega Lifesciences PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ฿331 Mil. Mega Lifesciences PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ฿146 Mil. Mega Lifesciences PCL's annualized Revenue for the quarter that ended in Mar. 2025 was ฿12,831 Mil. Mega Lifesciences PCL's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 was 0.04.


Mega Lifesciences PCL Debt-to-Revenue Historical Data

The historical data trend for Mega Lifesciences PCL's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Lifesciences PCL Debt-to-Revenue Chart

Mega Lifesciences PCL Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.03 0.03 0.02 0.03

Mega Lifesciences PCL Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.02 0.03 0.04

Competitive Comparison of Mega Lifesciences PCL's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Lifesciences PCL's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mega Lifesciences PCL's Debt-to-Revenue falls into.


;
;

Mega Lifesciences PCL Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Mega Lifesciences PCL's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(351.417 + 139.826) / 15344.136
=0.03

Mega Lifesciences PCL's annualized Debt-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(330.758 + 146.358) / 12830.704
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2025) Revenue data.


Mega Lifesciences PCL Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mega Lifesciences PCL's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Lifesciences PCL Business Description

Traded in Other Exchanges
Address
Debaratna Road, 909, Ample Tower, 9th Floor, Bangna Nuea, Bangna, Bangkok, THA, 10260
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.

Mega Lifesciences PCL Headlines

No Headlines